Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedNov 04, 2025
DataAggregated Company Financials
Companies21
  • 7D-5.8%
  • 3M5.1%
  • 1Y-51.5%
  • YTD-43.7%

Over the last 7 days, the Healthcare industry has dropped 5.8%, driven by Novo Nordisk declining 7.3%. On the other hand Zealand Pharma is actually up 5.6%. The industry has fallen 51% in the last year. As for the next few years, earnings are expected to grow by 6.1% per annum.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 04 Nov 2025DKK 1.9tDKK 448.0bDKK 141.9b17.4x13.4x4.2x
Thu, 02 Oct 2025DKK 2.1tDKK 447.4bDKK 141.7b18x15x4.8x
Sat, 30 Aug 2025DKK 2.1tDKK 447.4bDKK 141.7b23.9x14.6x4.6x
Mon, 28 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.1x19.9x5.9x
Wed, 25 Jun 2025DKK 2.5tDKK 423.3bDKK 124.5b30.1x19.8x5.8x
Fri, 23 May 2025DKK 2.4tDKK 424.3bDKK 125.1b23.7x19.5x5.8x
Sun, 20 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.8x19.1x5.7x
Tue, 18 Mar 2025DKK 2.9tDKK 409.5bDKK 121.3b25.2x24x7.1x
Thu, 13 Feb 2025DKK 3.1tDKK 408.2bDKK 118.3b26.2x26.5x7.7x
Sat, 11 Jan 2025DKK 3.4tDKK 387.5bDKK 111.3b29.8x30.2x8.7x
Mon, 09 Dec 2024DKK 4.0tDKK 387.3bDKK 111.3b31.3x36.3x10.4x
Wed, 06 Nov 2024DKK 3.9tDKK 373.0bDKK 107.1b32.7x36.1x10.4x
Fri, 04 Oct 2024DKK 4.0tDKK 372.0bDKK 107.1b36.1x37.8x10.9x
Sun, 01 Sep 2024DKK 4.8tDKK 372.0bDKK 107.2b35.5x44.6x12.9x
Tue, 30 Jul 2024DKK 4.5tDKK 355.4bDKK 106.3b36x42.6x12.7x
Thu, 27 Jun 2024DKK 5.0tDKK 355.4bDKK 106.2b34.3x47.5x14.2x
Sat, 25 May 2024DKK 4.7tDKK 355.3bDKK 106.2b37x44.1x13.2x
Mon, 22 Apr 2024DKK 4.4tDKK 341.3bDKK 99.6b33.3x44.5x13x
Wed, 20 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.2x46.2x13.5x
Fri, 16 Feb 2024DKK 4.4tDKK 340.0bDKK 98.7b34.7x44.2x12.8x
Sun, 14 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.5x42x11.8x
Tue, 12 Dec 2023DKK 3.5tDKK 320.6bDKK 90.0b33.2x38.8x10.9x
Thu, 09 Nov 2023DKK 3.7tDKK 319.4bDKK 89.9b32.1x41x11.5x
Sat, 07 Oct 2023DKK 3.4tDKK 305.5bDKK 82.2b33.2x41.4x11.1x
Mon, 04 Sep 2023DKK 3.5tDKK 305.4bDKK 82.2b36.7x42x11.3x
Wed, 02 Aug 2023DKK 3.0tDKK 287.2bDKK 75.5b36.7x39.8x10.5x
Fri, 30 Jun 2023DKK 2.9tDKK 287.1bDKK 75.5b39.1x38.8x10.2x
Sun, 28 May 2023DKK 3.1tDKK 287.1bDKK 75.5b41.8x41.4x10.9x
Tue, 25 Apr 2023DKK 3.2tDKK 272.5bDKK 68.5b44.5x46.4x11.7x
Thu, 23 Mar 2023DKK 2.8tDKK 292.5bDKK 69.2b38.2x40.9x9.7x
Sat, 18 Feb 2023DKK 2.8tDKK 289.4bDKK 68.9b40x40.4x9.6x
Mon, 16 Jan 2023DKK 2.7tDKK 276.0bDKK 66.3b38.4x40.3x9.7x
Wed, 14 Dec 2022DKK 2.7tDKK 276.0bDKK 66.3b38.9x40.5x9.7x
Fri, 11 Nov 2022DKK 2.5tDKK 275.1bDKK 66.7b36x37.3x9.1x
Price to Earnings Ratio

37.3x


Total Market Cap: DKK 2.5tTotal Earnings: DKK 66.7bTotal Revenue: DKK 275.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 35.4x202320242025
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 13.4x which is lower than its 3-year average PE of 35.4x.
  • The 3-year average PS ratio of 9.8x is higher than the industry's current PS ratio of 4.2x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 29% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-2.84%
Healthcare-5.80%
Life Sciences7.08%
Healthcare Services0.93%
Biotech0.65%
Healthtech-2.91%
Medical Equipment-3.88%
Pharma-6.90%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 24.8x.
    • Analysts are expecting annual earnings growth of 60.4%, which is higher than its past year's earnings decline of 47.6% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 89% over the next 5 years.
  • In contrast, the Biotech industry is expected to see its earnings decline by 10% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ZEAL Zealand PharmaDKK 500.608.9%
+DKK 2.9b		-39.5%PE5.3x
COLO B ColoplastDKK 610.401.9%
+DKK 2.5b		-31.1%PE33.7x
GMAB GenmabDKK 1.89k1.1%
+DKK 1.3b		24.4%PE13.1x
CHEMM ChemoMetecDKK 774.003.8%
+DKK 487.3m		99.5%PE72.3x
GUBRA GubraDKK 431.604.8%
+DKK 320.3m		3.5%PE4x

Latest News

ALK B
DKK 208.40
ALK-Abelló
7D
-1.2%
1Y
30.6%
COLO B
DKK 610.40
Coloplast
7D
1.9%
1Y
-31.1%
NOVO B
DKK 315.20
Novo Nordisk
7D
-4.9%
1Y
-57.7%
NNIT
DKK 54.80
NNIT
7D
-1.8%
1Y
-44.7%
GMAB
DKK 1,888.50
Genmab
7D
1.1%
1Y
24.4%

GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain

Genmab's fair value estimate has been raised from DKK 2,012.92 to DKK 2,017.35. Analysts highlight the Merus acquisition's positive impact on the late-stage pipeline and renewed confidence in royalty revenue growth opportunities.
CHEMM
DKK 774.00
ChemoMetec
7D
3.8%
1Y
99.5%

Earnings Tell The Story For ChemoMetec A/S (CPH:CHEMM) As Its Stock Soars 27%

Oct 31
Earnings Tell The Story For ChemoMetec A/S (CPH:CHEMM) As Its Stock Soars 27%
DEMANT
DKK 219.00
Demant
7D
-3.3%
1Y
-14.5%

DEMANT: Rising Share Buybacks Will Drive Medium-Term Upside Momentum

Analysts have modestly lowered their price target for Demant to DKK 284.19 from DKK 291.50, citing slight adjustments in the company’s discount rate, future profit margin, and anticipated revenue growth. Analyst Commentary Recent updates from major financial institutions have shed light on the divergent perspectives regarding Demant’s outlook and valuation potential.
HLUN B
DKK 46.10
H. Lundbeck
7D
-0.6%
1Y
5.6%

Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)

Oct 28
Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)
BAVA
DKK 235.10
Bavarian Nordic
7D
-0.6%
1Y
13.6%

Local Spread Of New Mpox Strain Will Challenge Future Vaccine Margins

Narrative Update on Bavarian Nordic Analysts have raised their fair value price target for Bavarian Nordic from €244 to €250, citing modest improvements in valuation assumptions and financial projections. What's in the News Officials in California have confirmed community spread of the new clade 1 Mpox strain among residents with no recent international travel.
STENO
DKK 1.57
Stenocare
7D
6.1%
1Y
21.7%
AMBU B
DKK 98.75
Ambu
7D
-5.8%
1Y
-15.7%
GUBRA
DKK 431.60
Gubra
7D
4.8%
1Y
3.5%
ZEAL
DKK 500.60
Zealand Pharma
7D
8.9%
1Y
-39.5%
VIRO
DKK 13.10
ViroGates
7D
2.7%
1Y
44.0%
PEG
DKK 0.10
Pharma Equity Group
7D
-7.7%
1Y
-37.7%

Here's Why Pharma Equity Group (CPH:PEG) Can Afford Some Debt

Aug 18
Here's Why Pharma Equity Group (CPH:PEG) Can Afford Some Debt
BIOPOR
DKK 1.28
BioPorto
7D
0.6%
1Y
-29.2%